The William Harvey Research Institute - Centre for Experimental Medicine and Rheumatology

Queen Mary University of London

Hypertension

Lorundrostat

Mineralys Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Queen Mary University of London | The William Harvey Research Institute - Centre for Experimental Medicine and Rheumatology

Site insights

Work at this site?

Active trials

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Trial sponsors